2899 results about "White blood cell" patented technology

The invention discloses an improved convolution neural network model for leukocyte calculation, and relates to the field of artificial intelligence and medical image processing. Aiming at the problems of inaccurate feature extraction, strong background noise interference and insufficient multi-scale feature fusion in a traditional leukocyte calculation method, the model realizes fine processing and feature enhancement of a medical image through a multi-level modular design; the image preprocessing module is used for completing white blood cell positioning and image adaptive division and enhancement; multi-scale edge, texture and gray features are fused by means of an image feature extraction module, and a composite feature vector is constructed; through multi-scale convolution, a double-layer attention mechanism and convolution layer calculation of the improved convolution neural network model module, precise focusing of white blood cell contours and cell nucleus features, background noise suppression and calculation efficiency optimization are realized; and finally, a calculation result is output through a visual terminal, so that the accuracy and robustness of leukocyte counting are remarkably improved, and efficient technical support is provided for medical microscopic image analysis.

The invention discloses a probiotic with the depression improving effect and a microecological preparation and application thereof, and is characterized in that the probiotic comprises lactobacillus mucus PC17 with the preservation number of CGMCC No.33866, the active ingredients of the lactobacillus microecological preparation comprise thalli of the lactobacillus mucus PC17, and a preparation method of the microecological preparation comprises the following steps: adding the lactobacillus mucus PC17 into the lactobacillus mucus PC17, uniformly mixing the lactobacillus mucus PC17, the lactobacillus mucus PC17, the lactobacillus mucus PC17, the lactobacillus mucus PC17, the lactobacillus mucus PC17, the lactobacillus mucus PC17 and the lactobacillus mucus PC17 The lactic acid bacteria are inoculated into a fermentation culture medium according to a volume ratio of 1-5% to prepare the lactic acid bacteria microecological preparation, can be used for preparing antidepressant drugs, and has the advantages of being capable of promoting RIN14B cells to secrete 5-hydroxytryptamine and 5-hydroxytryptophan, reducing the levels of interleukin-1beta, interleukin-6, tumor necrosis factor-alpha, corticosterone and corticotropin in serum, and improving the antidepressant activity of the antidepressant drugs. The levels of aminobutyric acid and brain-derived neurotrophic factors in serum are improved, and the depression-like behaviors of CUMS depression model mice are obviously improved.

The invention provides a preparation method and application of casei paracasei IOB413 after-generation powder, and relates to the field of microorganisms. Tartary buckwheat is used as a solid-state fermentation culture medium, and the lactobacillus paracasei IOB413 is fermented and then crushed to prepare the lactobacillus paracasei IOB413 after-generation powder with high flavone content. The flavonoid content of the metagenic powder prepared by the method is far higher than that in tartary buckwheat and casei paracasei IOB413, the levels of tumor necrosis factor alpha (TNF-alpha) and interleukin (IL-6) can be reduced, the level of anti-inflammatory factor interleukin (IL-10) can be increased, the gingival index and the dental plaque index can be reduced, the growth of streptococcus mutans can be inhibited to a certain extent, and the metagenic powder can be used for preventing and treating the dental plaque. The oral micro-ecology is improved.

The invention provides an esophageal cancer marker screening method based on enzyme transfer method methylation sequencing, which comprises the following steps: S1, collecting esophageal early cancer and para-carcinoma tissue samples, and carrying out enzyme transfer method whole genome methylation sequencing; s2, integrating methylation data of esophageal cancer and para-carcinoma tissues in databases of TCGA, GEO, MethMarker DB and the like; s3, screening differential methylation sites, preferably sites which are hypermethylated in esophageal cancer but hypomethylated in samples such as leukocytes, so as to reduce plasma background interference; s4, obtaining a candidate marker combination based on an integrated methylation feature screening model of LASSO regression and a random forest algorithm; s5, constructing a classifier model based on the candidate marker combination, carrying out training and reasoning test on the model, and evaluating the prediction performance of the model; and S6, obtaining the esophageal cancer marker combination. According to the method, enzyme transfer sequencing and machine learning are combined, the marker prediction accuracy is remarkably improved, and a new reference is provided for clinical research of esophageal cancer.

The present invention provides antibodies, or antigen binding fragments thereof, capable of binding to leukocyte immunoglobulin-like receptor subfamily B member 2 (LILRB2). The invention also provides application of the antibody or the antigen binding fragment thereof in preparation of drugs for treating diseases related to high expression of LILRB2. The antibody or the antigen binding fragment thereof provided by the invention can bind to human LILRB2 with high affinity, block the binding of the LILRB2 and the ligand HLA-G thereof, and enhance the T cell function.

The invention relates to the technical field of target detection, and discloses a blood cell detection method based on improved YOLOv8. According to the method, a convolutional attention module (CBAM) is introduced, so that the detection performance of the model on a shielded small target is improved; a new loss function S-MPDIOU is set, so that the accuracy and robustness of the loss function are further improved; the multi-scale feature fusion technology is adopted to better capture blood cell information of different sizes, so that the model can more accurately identify small target platelets; the recall rate is improved by improving a non-maximum suppression (NMS) algorithm, and particularly under the condition of dense blood cells or complex forms, the improved NMS algorithm can more effectively solve the overlapping problem and reduce false detection and missing detection. Through testing, the model can accurately identify and position different types of blood cells such as red blood cells, white blood cells and blood platelets in an image, and a new effective method is provided for blood cell detection.

A sample preparation instrument with an integrated device for estimating a concentration of white blood cells in a specimen is described. The sample preparation instrument receives a specimen for which a sample is to be prepared for analysis. The integrated device can implement an optical method, an electrical resistance method, or a flow cytometry method, for example, to estimate the white blood cell concentration in the specimen. For some types of analysis, a sample volume of the specimen is dependent on the white blood cell concentration. Therefore, the sample preparation instrument can automatically determine and adjust the sample volume of the specimen based on the estimated white blood cell concentration prior to adding additional reagents, such as labeling reagents and / or lytic reagents, to prepare the sample.

Provided are methods of using a compound that binds to interleukin- 1 beta (IL- 1β) at a binding pocket of IL- 1β identified herein, which traps the IL- 1β and inhibits its interaction with interleukin- 1 receptor type I (IL-1R1).

Disclosed are methods of treating a subject having clinically significant signs and symptoms associated with blood cell differentiation and treated with an agent that reduces the level and / or activity of BRG1 and / or BRM. The methods disclosed herein may include, e.g., administering to the subject an effective amount of a corticosteroid, hydroxyurea, or furosemide, or subjecting the subject to leukapheresis.

Fusion proteins are provided that consist of essential elements such as one or more proteins / polypeptides capable of transporting into the endoplasmic reticulum (ER) and fragments or variants of interleukin 18 (IL-18) or IL-18. The proteins / polypeptides capable of transporting into the ER include, but are not limited to, immune globular proteins (e.g., Fc regions, VHH antibodies, and scFv), and globular proteins (e.g., serum albumin). In some embodiments, the IL-18 may be a pro-IL-18 similar to a natural precursor cytokine, wherein IL-18 is fused to the C-terminus of a propeptide or a propeptide variant thereof. In some embodiments, the fusion protein may further comprise a cleavable peptide linker.

The disclosure provides interleukin 21 (IL-21) variants that have (i) decreased or no binding to a human interleukin 21 receptor (IL-21R) as compared to a wild-type human IL-21 polypeptide; or (ii) increased stability as compared to a wild-type human IL-21 polypeptide; or (iii) decreased or no binding to a human interleukin 21 receptor (IL-21R) as compared to a wild-type human IL-21 polypeptide and increased stability as compared to a wild-type human IL-21 polypeptide. The disclosure also provides fusion proteins including an antibody or fragment thereof bound, e.g., covalently linked, to an IL-21 variant.

The invention relates to the technical field of antibodies, and provides an anti-CD45 antibody for detecting a white blood cell common antigen based on flow cytometry and application of the anti-CD45 antibody, the antibody comprises at least one of the following CDRs: a heavy chain variable region CDR: an amino acid sequence of SEQ ID NO: 1-3 or a conservatively modified form thereof; and a light chain variable region CDR: SEQ ID NO: 4-6 or an amino acid sequence in a conservative modification form thereof. The antibody or the antigen binding fragment thereof can efficiently and specifically recognize CD45, and can effectively detect the CD45.

The invention relates to a culture medium and a culture method of persistent DC-CIK cells and application of the culture medium and the culture method, and belongs to the technical field of cell culture. The invention provides a culture medium for persistent DC-CIK cells, which takes a serum-free culture medium as a solvent and comprises a recombinant human granulocyte macrophage colony stimulating factor, a recombinant human interleukin-12, a recombinant human tumor necrosis factor-alpha, a recombinant human interferon-gamma, L-cysteine, glutathione, ginseng polysaccharide and streptomycin sulfate. According to the culture medium and the culture method of the persistent DC-CIK cells, proliferation and growth of the DC-CIK cells can be promoted, and very high tumor killing activity of the DC-CIK cells can be maintained for a long time.

The invention provides a mesenchymal stem cell preparation for promoting knee joint repair as well as a preparation method and application thereof, and belongs to the technical field of medicines. The preparation method comprises the following steps: loading transforming growth factor-beta1 and interleukin-6 on chitosan microspheres, then preparing a chitosan-oxidized starch-carboxymethyl-beta-cyclodextrin bracket loaded with sustained release microspheres, loading luteolin and quercetin, carrying out mixed culture with mesenchymal stem cells, adding a traditional Chinese medicine extract, and carrying out freeze-drying to obtain the luteolin-quercetin-modified mesenchymal stem cells. The mesenchymal stem cell preparation for promoting knee joint repair is prepared. The preparation method of the carbon anode plate for fluorine preparation is simple, the generation of polarization of the carbon anode plate is prevented, and the carbon anode plate has the advantages of low porosity, low ash content, high mechanical strength, high volume density, obviously prolonged service life, low resistivity and the like, and has a wide application prospect.

The present invention relates to an intestinal epithelium model accurately reproducing the pathophysiological mechanisms observed in vivo in the context an inflammatory condition of the intestinal barrier. The model according to the present invention comprises two compartments separated by a semi-permeable membrane. The first compartment, corresponding to the apical pole of the intestinal epithelium, comprises a coculture of Caco-2 cells differentiated into enterocytes and HT29-MTX cells differentiated into goblet cells. The second compartment, corresponding to the basolateral pole of the intestinal epithelium, comprises a culture of THP-1 monocytic cells differentiated into macrophages. The model according to the present invention is characterized in that the cells contained in the first compartment produce interleukin 6 (IL-6) at a concentration of more than 100 pg / ml and interleukin 8 (IL-8) at a concentration of more than 150 pg / ml, and the cells contained in the second compartment produce tumour necrosis factor α (TNF-α) at a concentration of more than 40 pg / ml and interleukin 1β (IL-1β) at a concentration of more than 90 pg / ml. The present invention also relates to the method for obtaining this model and also to a method for selecting candidate compounds for the treatment of inflammatory bowel diseases by verifying their ability to stop the inflammation as soon as the permeability is increased, or verifying the restoration of the permeability and of the mucus layer.

The invention discloses application of burdock root polysaccharide in preparation of a medicine for treating cognitive impairment, and belongs to the technical field of traditional Chinese medicines. Experiments prove that the burdock root polysaccharide can improve cognitive impairment and autonomous exploration ability of D-galactose induced cognitive impairment model mice, increase the activity of superoxide dismutase in serum of the mice, reduce the content of malondialdehyde, reduce the content of hippocampus interleukin-1beta and tumor necrosis factor-alpha in brains of the mice, and improve the cognitive impairment activity of the mice. According to the present invention, with the composition, the loss of the neuron in the hippocampal region of the cognitive impairment model mouse can be reduced so as to achieve the neuron protection effect, such that the good treatment effect on the cognitive impairment can be provided, and the new approach is provided for the development of the cognitive impairment-related drug.

The invention discloses a chicken infectious anemia virus subunit vaccine, and belongs to the technical field of animal disease vaccines. The invention provides a chicken infectious anemia virus subunit vaccine. Active ingredients of the chicken infectious anemia virus subunit vaccine are recombinant fusion protein of chicken infectious anemia virus VP1 protein B cell epitope and salmonella typhimurium flagellin. The B cell epitope of the chicken infectious anemia virus VP1 protein is obtained by connecting B cell antigen epitopes contained in the chicken infectious anemia virus VP1 protein through a connecting peptide. The salmonella typhimurium flagellin is obtained by deleting a hypervariable region of the salmonella typhimurium flagellin FliC. The fusion expression protein provided by the invention can induce generation of a specific IgG antibody after one-day-old SPF chicken, and after immunization for 28 days, immunized chicken flocks can resist challenge of chicken infectious anemia virus virulent strains, and 70% of challenge chicken flocks are protected without disease attack. The invention has great potential for clinical prevention and control of chicken infectious anemia virus infection.

The invention discloses an anti-human inflammatory factor interleukin 6 monoclonal antibody and an application thereof. When the monoclonal antibody is prepared, an adopted immunogen is a human inflammatory factor interleukin 6 antigen, and an amino acid sequence of the human inflammatory factor interleukin 6 antigen comprises a sequence as shown in SEQ ID NO: 1. A group of monoclonal antibodies specifically combined with antigens is constructed based on the IL-6 antigens. The IL-6 monoclonal antibody has strong binding capacity with an IL-6 antigen in a clinical sample, has no cross reaction with other proteins, has good specificity and affinity compared with a commercial antigen, can be effectively applied to ELISA and a dry-type immunofluorescence method, has good detection linearity, precision, stability and accuracy, and can be widely applied to the field of immunoassay. The antibody can be combined with the antigen to serve as a detection reagent raw material combination, and has clinical detection advantages.

The invention relates to a method for determining at least part of the cellular composition of at least one biological sample comprising leukocytes, wherein the proportion of at least one type of leukocyte is determined based on the identified methylation levels, in order to predict the relative distribution of that type of leukocyte in the sample. The invention further relates to the use of at least one artificial nucleic acid molecule for determining at least part of the cellular composition of a biological sample comprising leukocytes according to the above-mentioned method. In the context of the invention, the following CpG sites according to the invention with cell-type-specific methylation could be identified: cg22381196 (DHODH), cg12483340 (TMEM87A), cg06270401 (DYRK4), cg23054181 (FAM169BP), cg26076724 (RP11-146I2.2), cg12249234 (KSR1), cg04468741 (MICAL2), cg05074138 (CTLA4), cg05705140 (LINC01237), cg15564619 (SKI), cg11531557 (HMBOX1), cg02212339 (TRPV1), cg22488278 (ZFYVE28), cg02240030 (MAD1L1) and cg24408769 (JARID2).

The invention provides a method for predicting binding affinity of human leukocyte antigen I-type molecules and peptide fragments, and a construction method of the method comprises the following steps: acquiring antigen binding site residues of the human leukocyte antigen I-type molecules, and extracting antigen binding region sequences of the human leukocyte antigen I-type molecules through secondary multi-sequence alignment; respectively generating a human leukocyte antigen class I molecule coding matrix and a peptide fragment coding matrix based on the paired human leukocyte antigen class I molecule-peptide fragment; and then constructing a model of a convolutional neural network to quantify the binding affinity score of the human leukocyte antigen class I molecule and the peptide fragment. The invention develops a method for predicting binding affinity of human leukocyte antigen class I molecules and peptide fragments based on a convolutional neural network by combining physicochemical characteristics of amino acids, complementary epitope sequences of the human leukocyte antigen class I molecules and an interaction relationship among the sequences.

Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein. The universal donor cells comprise at least one genetic modification within or near at least one gene that encodes a survival factor, wherein the genetic modification comprises an insertion of a polynucleotide encoding a tolerogenic factor. The universal donor cells may further comprise at least one genetic modification within or near a gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or a component or a transcriptional regulator of a MHC-I or MHC-II complex, wherein said genetic modification comprises an insertion of a polynucleotide encoding a second tolerogenic factor.

The present invention relates to the technical field of chemical pharmacy, and in particular to a compound for degradation of a targeted interleukin-1 receptor-associated kinase 4 (IRAK4), and a pharmaceutically acceptable salt of the compound. The compound can be used for treating or preventing IRAK4-mediated immune diseases, inflammatory diseases, and cancers.

The present disclosure provides methods of treating an immune-mediated disease in a subject in need thereof. The present disclosure provides methods of treating atopic dermatitis in a subject in need thereof. The present disclosure provides methods of treating moderate-to-severe atopic dermatitis in a subject in need thereof. The present disclosure provides a method of treating atopic dermatitis (AD) in a subject in need thereof, comprising selecting a subject having AD and an elevated level of at least one biomarker selected from the group consisting of thymus and activation-regulated chemokine (TARC), interleukin-5 (IL-5), eosinophil count, and lactate dehydrogenase (LDH) relative to a control.

The invention relates to the technical field of biological products, and discloses a mesenchymal stem cell hair growth liquid and a preparation method thereof, and the mesenchymal stem cell hair growth liquid comprises the following components: hair follicle mesenchymal stem cells; a hair follicle mesenchymal stem cell exosome; growth factors: a vascular endothelial growth factor (VEGF), a fibroblast growth factor (FGFs), a keratinocyte growth factor (KGF-7) and interleukin-10 (IL-10); vitamins: vitamin E, vitamin B5, vitamin B2, vitamin B6, vitamin C and biotin; the plant extracts comprise a cacumen biotae extract, a polygonum multiflorum extract, a ginseng extract, a peppermint extract, a purslane extract and a rhodiola rosea extract; other active ingredients: tripeptide and digoxin; the auxiliary material is a hyaluronic acid-collagen peptide graft copolymer; and the balance of a phosphate buffer solution.

The present invention provides a cell line for specific quantitative calibration of interleukin 7 (IL-7) activity and its application. Specifically, the present invention provides a construct, a vector, a host cell, a kit and its application and preparation method. The construct, the vector, the host cell and the kit of the present invention can be used to construct an IL-7 reporter cell for specific quantitative calibration of interleukin 7 (IL-7) activity, thereby achieving stable, highly accurate and highly sensitive quantitative detection of IL-7 activity, and providing accurate quality control means for the development of IL-7 related drugs.

The application presently discloses a method of treating atherosclerosis in a human subject comprising administering an effective amount of an IL-8 inhibitor, an IL-6 inhibitor, and / or an IL-1β inhibitor, wherein the subject has a TET2 and / or DNMT3A mutation thereby treating atherosclerosis. It also discloses a method for treating atherosclerosis in a human subject comprising sequencing at least a part of a genome comprising TET2 and / or DNMT3A of one or more cells in a blood sample of the subject; determining from the sequencing whether the subject has one or more mutations in TET2 and / or DNMT3A, if it is determined that the subject has at least one TET2 and / or DNMT3A mutation, administering an IL-8 inhibitor, an IL-6 inhibitor, and / or an IL-1β inhibitor to a subject to the subject thereby treating atherosclerosis.

The invention belongs to the technical field of chemical drugs, provides an interleukin-17A / F inhibitor as well as a preparation method and application thereof, and particularly relates to a compound as shown in a general formula (I), or a racemate, an isomer or medicinal salt thereof, which is used for treating diseases such as psoriasis and arthritis as the IL-17A / F inhibitor.

The invention provides an aurone compound and medical application thereof, and relates to an aurone compound and application thereof in preparation of drugs for preventing and treating myelosuppression or blood system diseases. The aurone compound provided by the invention can significantly improve the myelosuppression state caused by rusotinib and radiotherapy, can recover the generation of erythrocytes after mouse irradiation and use of rusotinib, and has a significant effect on the recovery of leukocytes, especially neutrophils and lymphocytes, of the irradiated mouse. The invention provides a new potential drug for treatment of myelosuppression or blood system diseases.

The invention discloses a panda-derived feline panleucopenia virus RAA-CRISPRCas12a detection method, and belongs to the technical field of virus detection, and the panda-derived feline panleucopenia virus RAA-CRISPRCas12a detection method comprises the following steps: S1, primer and probe design; s2, screening an RAA amplification primer; s3, RAA reaction condition optimization; s4, performing RAA sensitivity and specificity verification; s5, preparing crRNA (Complementary Ribonucleic Acid); s6, optimal crRNA screening is carried out; s7, optimizing the RAA-CRISPR / Cas12a (Reverse Amplified Architecture- S8, the specificity and the sensitivity of the RAA-CRISPR / Cas12a are verified; s9, clinical sample detection; according to the invention, by elaborately designing a primer and a probe aiming at the capsid protein VP2 gene of the feline parvovirus (FPV), fully utilizing the advantages of recombinase-mediated amplification (RAA) and a CRISPR / Cas12a system, and comprehensively optimizing reaction conditions and components of the system, the detection method has remarkable advantages, can quickly complete the detection process under the condition of constant temperature of 37 DEG C, is extremely high in sensitivity, and can be used for rapidly detecting the feline parvovirus. The lowest detection limit can reach 1 * 10 < 1 > copies / mu L, the specificity is high, and the coincidence rate with a real-time fluorescent quantitative PCR method is as high as 100%.

The present disclosure relates to compositions and methods of reducing, mitigating, or eliminating endogenous IL-2 signaling and / or binding to the IL-2 alpha-beta-gamma receptor using bi-functional molecules.